The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Gastrointestinal

Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis
Finance

Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis

APR 28, 2022
Protecting the human intestinal microbiome with synthetic biology
Gastrointestinal

Protecting the human intestinal microbiome with synthetic biology

APR 18, 2022
Deciphering gut microbiome ‘chatter’ to combat IBD
Gastrointestinal

Deciphering gut microbiome ‘chatter’ to combat IBD

MAR 14, 2022
BioGaia’s probiotic reduces inflammation in patients with diverticulitis
Biotics and Supplements

BioGaia’s probiotic reduces inflammation in patients with diverticulitis

FEB 9, 2022
Engineered yeast probiotic developed to treat inflammatory bowel disease
Biotics and Supplements

Engineered yeast probiotic developed to treat inflammatory bowel disease

JUL 7, 2021
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
Finance

Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease

JUN 22, 2021
Researchers explore microbial ecosystem in search of drugs to fight SARS-CoV-2
Gastrointestinal

Researchers explore microbial ecosystem in search of drugs to fight SARS-CoV-2

JUN 20, 2021
A new study by ImmunoBiome-POSTECH research team identifies new drug candidate targeting multiple sclerosis and inflammatory bowel disease
Gastrointestinal

A new study by ImmunoBiome-POSTECH research team identifies new drug candidate targeting multiple sclerosis and inflammatory bowel disease

JUN 16, 2021
Healthy Microbiome Designed by Gusto Global Shows Promise to Radically Change Treatment for Inflammatory Diseases
Gastrointestinal

Healthy Microbiome Designed by Gusto Global Shows Promise to Radically Change Treatment for Inflammatory Diseases

JUN 11, 2021
Emulate Launches Colon Intestine-Chip to Advance Research of Inflammatory Intestinal Diseases
Gastrointestinal

Emulate Launches Colon Intestine-Chip to Advance Research of Inflammatory Intestinal Diseases

APR 13, 2021
Digbi Health Raises $5.4 Million in Series A Funding to Reverse Obesity and Associated Inflammatory Digestive and Skin Illnesses
Finance

Digbi Health Raises $5.4 Million in Series A Funding to Reverse Obesity and Associated Inflammatory Digestive and Skin Illnesses

APR 9, 2021